Oral GLP-1 Medicines: Approval and Clinical-Trial Evidence Tracker

Oral GLP-1 medicines are not a single interchangeable product. Oral semaglutide is a peptide-based medicine; orforglipron is a nonpeptide small molecule. Both act at the GLP-1 receptor, but their formulations, regulatory decisions and clinical evidence have to be checked separately.

This tracker connects two US approval records with the primary obesity trials behind the headlines. It separates what a regulator authorised from what a particular study measured, so a brand name or percentage does not have to carry more meaning than the source supports.

Sources checked: 25 October 2026. This is a selected, dated evidence reference, not a live prescribing or availability service. The approval table covers the US FDA decisions identified below. For Australian registration and subsidy, use our separate GLP-1 Australia status guide.

Oral GLP-1 approval tracker: check the formulation and jurisdiction

Read the product record, not just the ingredient name. A familiar molecule can appear in different brands, formulations and indications. An older approval for the active ingredient does not date the approval of a newer finished product.

For example, the Wegovy tablet label includes an initial US approval year of 2017, while the tablet application’s approval letter is dated December 2025. Those entries answer different historical questions. Using the formulation-specific letter prevents a misleading timeline.

Clinical-trial dataset: OASIS 4 and ATTAIN-1

The following are two separate placebo-controlled trials. They were not a direct comparison between oral semaglutide and orforglipron. Values are selected results from the linked primary publications; they are not predictions of an individual’s response.

These papers also report safety and treatment discontinuation. Reading only weight change discards part of the evidence. In ATTAIN-1, gastrointestinal events were the most frequent adverse effects, and adverse events led some participants to discontinue treatment. That finding belongs alongside the efficacy result, not in a separate sales-style footnote.

Trial identifiers make the underlying programme traceable. The linked registry records identify the studies; the linked publications supply the results summarised here. A registry entry by itself is not evidence that an intervention worked.

Why do headlines give different weight-loss percentages?

A trial can estimate more than one question. One analysis may follow the intended treatment assignment despite discontinuation or other events. Another may estimate an outcome under continued adherence to the studied intervention. These are different estimands: precise definitions of the effect being estimated.

The ATTAIN-1 paper’s treatment-regimen result above should therefore not be silently exchanged for the 12.4% efficacy-estimand figure in the sponsor’s detailed trial announcement. The analysis label is part of the number. A larger percentage is not automatically the more relevant answer to every reader’s question.

The same discipline applies to percentages versus percentage points. A change in a person’s body weight and a difference between treatment groups are different quantities. Our clinical-trial reading guide explains comparators, endpoints, discontinuation and uncertainty.

Peptide versus small molecule: why “pill” does not define the chemistry

“Oral” describes a route. “GLP-1 receptor agonist” describes a target-related action. “Peptide” and “small molecule” describe molecular structure. These labels belong to different levels of the explanation.

Orforglipron is explicitly described as a nonpeptide small-molecule GLP-1 receptor agonist in the primary ATTAIN-1 paper. Semaglutide is a GLP-1 analogue described in the FDA tablet label. Their common receptor does not make their chemical structures or finished formulations interchangeable.

For the terminology behind this distinction, start with GLP-1 hormone, receptor and medicine, then the peptide, protein and small-molecule classification guide.

A five-field check for an oral-drug comparison

1. Product: identify the active ingredient, brand and formulation.
2. Decision: name the regulator, jurisdiction, indication and decision date.
3. Study: identify the trial, population, comparator and endpoint time.
4. Analysis: keep the estimand and missing-data approach attached to the result.
5. Limits: include uncertainty, adverse events and what was not directly compared.

Shared branding is not a substitute for the first field; a press-release headline is not a substitute for all five. Oral formulation also does not establish lower risk or equivalent outcomes. The current manufacturer-hosted Foundayo prescribing information and the linked FDA tablet label contain important warnings and contraindications that a short comparison cannot reproduce completely.

US evidence, European decisions and Australian status need separate records

The FDA matrix above should not be read as a global availability table. Our Foundayo European assessment article covers its October 2026 EMA opinion. An assessment opinion, a final authorisation, a local product registration and reimbursement are distinct events.

Australian readers should follow the TGA/PBS status page for local context. Broader emerging programmes, including amylin approaches, are covered in the obesity-trial results tracker and our amylin-versus-GLP-1 explainer.

Scope, sources and maintenance

This edition selects two formulation-specific US approval records and two pivotal published obesity trials. It is not an exhaustive list of oral diabetes medicines or investigational compounds. Historical approval letters establish their dated decisions; they do not replace current product labelling or prove a later decision in another jurisdiction.

Update triggers are a verified regulator decision, a material label revision or a new primary trial publication. Each future revision should retain the trial identifier and distinguish a new source check from the original event date. No automated live-refresh claim is made.

• FDA application records and labels: Wegovy tablets, NDA 218316; Foundayo, NDA 220934.
• Primary results: OASIS 4; ATTAIN-1.

Educational evidence reference. No personal treatment recommendation, administration instructions or purchasing guidance.